At the beginning of 2020, an update to the CAP/ASCO ER/PgR testing guidelines in breast cancer was released. This webinar will review what has changed, what has stayed the same and how these changes might affect ER/PgR testing standard operating procedures, interpretation and reporting in your laboratory. Case-based examples of application of the recommendations will be provided and frequently asked questions about the update will be answered.
- Identify new aspects of the CAP/ASCO ER/PgR testing in breast cancer guideline updates that affect hormone receptor standard testing operating procedures, interpretation and reporting for invasive breast cancer and ductal carcinoma in situ.
- Review how to apply the new recommendations in specific ER/PgR testing patient care scenarios.
Kimberly Allison, MD